Tosedostat

N/A

Report date: 2023/11/30 11:27:53
NME

Base Information

Drug NameTosedostat
Drug Alias NameTosedostatum托多司他托舍多特CHR-2797BB-76163
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAminopeptidase inhibitors
TargetsAminopeptidase
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCti Biopharma CorpVernalis Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWeill Medical College of Cornell UniversityCell Therapeutics IncWashington University School Of Medicine +[7] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursMyelodysplastic SyndromesCarcinoma, Non-Small-Cell Lung +[7] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG